Trial
NCT03705169
Pharmacokinetics and Safety of SAR441236
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Sanofi; ModeX Therapeutics, An OPKO Health Company
Condition
HIV-1-infection
Intervention
SAR441236
Why stopped
The study closed to enrollment and follow-up in May 2023. There had been no enrollment since October 2021, and by 2023, the available study product had reached its expiration date. Enrollment targets in Arm B had not been met.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-12